1. Home
  2. DAWN vs ESE Comparison

DAWN vs ESE Comparison

Compare DAWN & ESE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • ESE
  • Stock Information
  • Founded
  • DAWN 2018
  • ESE 1990
  • Country
  • DAWN United States
  • ESE United States
  • Employees
  • DAWN N/A
  • ESE N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • ESE Telecommunications Equipment
  • Sector
  • DAWN Health Care
  • ESE Telecommunications
  • Exchange
  • DAWN Nasdaq
  • ESE Nasdaq
  • Market Cap
  • DAWN 658.9M
  • ESE 4.9B
  • IPO Year
  • DAWN 2021
  • ESE N/A
  • Fundamental
  • Price
  • DAWN $6.63
  • ESE $191.38
  • Analyst Decision
  • DAWN Strong Buy
  • ESE Strong Buy
  • Analyst Count
  • DAWN 7
  • ESE 2
  • Target Price
  • DAWN $31.57
  • ESE $187.50
  • AVG Volume (30 Days)
  • DAWN 1.3M
  • ESE 220.0K
  • Earning Date
  • DAWN 07-29-2025
  • ESE 08-06-2025
  • Dividend Yield
  • DAWN N/A
  • ESE 0.17%
  • EPS Growth
  • DAWN N/A
  • ESE 19.62
  • EPS
  • DAWN N/A
  • ESE 4.56
  • Revenue
  • DAWN $161,922,000.00
  • ESE $1,071,861,000.00
  • Revenue This Year
  • DAWN $17.98
  • ESE $17.26
  • Revenue Next Year
  • DAWN $49.50
  • ESE $14.04
  • P/E Ratio
  • DAWN N/A
  • ESE $42.23
  • Revenue Growth
  • DAWN N/A
  • ESE 8.40
  • 52 Week Low
  • DAWN $6.08
  • ESE $108.70
  • 52 Week High
  • DAWN $16.76
  • ESE $196.13
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 49.13
  • ESE 56.11
  • Support Level
  • DAWN $6.69
  • ESE $184.54
  • Resistance Level
  • DAWN $7.24
  • ESE $194.65
  • Average True Range (ATR)
  • DAWN 0.27
  • ESE 4.08
  • MACD
  • DAWN 0.04
  • ESE -0.47
  • Stochastic Oscillator
  • DAWN 46.57
  • ESE 59.02

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About ESE ESCO Technologies Inc.

ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace and Defense, Utility Solutions Group (USG), and Test. The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.

Share on Social Networks: